Comparative Pharmacology
Head-to-head clinical analysis: METHOTREXATE PRESERVATIVE FREE versus PYQUVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHOTREXATE PRESERVATIVE FREE versus PYQUVI.
METHOTREXATE PRESERVATIVE FREE vs PYQUVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to tetrahydrofolate, thereby inhibiting thymidylate and purine synthesis, leading to impaired DNA synthesis, repair, and cellular replication. It also exhibits immunomodulatory and anti-inflammatory effects through adenosine-mediated pathways.
Pyquvi (vadadustat) is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. It stabilizes HIF-2α, promoting erythropoietin production and iron mobilization, thereby stimulating erythropoiesis.
Rheumatoid arthritis: 7.5 mg orally once weekly. Psoriasis: 10-25 mg orally once weekly. Neoplastic diseases: IV or IM 30-40 mg/m² once weekly, or oral 2.5-5 mg every 12 hours for 3 doses once weekly. Intrathecal: 12 mg/m² (maximum 15 mg) every 2-7 days.
400 mg orally once daily with food, continued until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life is 3-10 hours for low doses (≤50 mg/m²) and 8-15 hours for high doses (>1 g/m²); prolonged to 24-48 hours in patients with third-space effusions or renal impairment.
The terminal elimination half-life is approximately 50 hours (range 40–60 hours), supporting once-daily dosing. Steady-state is achieved within 2–3 weeks of continuous dosing.
Renal excretion (80-90% as unchanged drug via glomerular filtration and active tubular secretion; enterohepatic recirculation occurs; fecal elimination <10%).
Primarily hepatic metabolism via CYP3A4 and UGT1A9, with less than 5% of the dose excreted unchanged in urine. Fecal excretion accounts for approximately 70% of total clearance, primarily as metabolites.
Category D/X
Category C
Antimetabolite
Antimetabolite